Dalia M Dawoud

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3403492/publications.pdf

Version: 2024-02-01

63 papers 1,008 citations

471509 17 h-index 28 g-index

71 all docs

71 docs citations

times ranked

71

1896 citing authors

#	Article	IF	CITATIONS
1	Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe. Journal of Asthma, 2023, 60, 76-86.	1.7	4
2	Diagnostics and Treatments of COVID-19: A Living Systematic Review of Economic Evaluations. Value in Health, 2022, 25, 773-784.	0.3	13
3	Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges. Pharmacoeconomics, 2022, , 1.	3.3	6
4	Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS. Clinical Epidemiology, 2022, Volume 14, 369-384.	3.0	11
5	Capturing what matters: updating NICE methods guidance on measuring and valuing health. Quality of Life Research, 2022, 31, 2167-2173.	3.1	10
6	Current Approaches to Vaccine Safety Using Observational Data: A Rationale for the EUMAEUS (Evaluating Use of Methods for Adverse Events Under Surveillance-for Vaccines) Study Design. Frontiers in Pharmacology, 2022, 13, 837632.	3.5	8
7	Venous thromboembolism prophylaxis in patients undergoing knee replacements: comparison of real-world outcomes. International Journal of Clinical Pharmacy, 2021, 43, 621-628.	2.1	4
8	Emerging from the other end: Key measures for a successful COVID-19 lockdown exit strategy and the potential contribution of pharmacists. Research in Social and Administrative Pharmacy, 2021, 17, 1950-1953.	3.0	32
9	Drive-thru pharmacy services: A way forward to combat COVID-19 pandemic. Research in Social and Administrative Pharmacy, 2021, 17, 1920-1924.	3.0	45
10	Pharmacy practice research priorities during the COVID-19 pandemic: Recommendations of a panel of experts convened by FIP Pharmacy Practice Research Special Interest Group. Research in Social and Administrative Pharmacy, 2021, 17, 1903-1907.	3.0	16
11	COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries. Rheumatology, 2021, 60, SI37-SI50.	1.9	37
12	Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study. BMJ, The, 2021, 373, n1038.	6.0	50
13	The Sandbox Approach and its Potential for Use in Health Technology Assessment: A Literature Review. Applied Health Economics and Health Policy, 2021, 19, 857-869.	2.1	14
14	Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom. International Journal of Obesity, 2021, 45, 2347-2357.	3.4	20
15	Characteristics and Outcomes of Over 300,000 Patients with COVID-19 and History of Cancer in the United States and Spain. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1884-1894.	2.5	6
16	Raising the bar for using surrogate endpoints in drug regulation and health technology assessment. BMJ, The, 2021, 374, n2191.	6.0	19
17	Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment. Pharmacoeconomics, 2021, 39, 275-285.	3.3	42
18	Assessing Technologies for COVID-19: What are the Challenges for Health Technology Assessment Agencies? Findings From a Survey and Roundtable Workshop. Pharmacoeconomics, 2021, 39, 1455-1463.	3.3	5

#	Article	IF	CITATIONS
19	Characteristics and outcomes of patients with COVID-19 with and without prevalent hypertension: a multinational cohort study. BMJ Open, 2021, 11, e057632.	1.9	8
20	Generosity, collegiality, and scientific accuracy when writing and reviewing original research. Research in Social and Administrative Pharmacy, 2020, 16, 261-265.	3.0	16
21	Cost-Effectiveness of Antiviral Treatments for Pandemics and Outbreaks of Respiratory Illnesses, Including COVID-19: A Systematic Review of Published Economic Evaluations. Value in Health, 2020, 23, 1409-1422.	0.3	22
22	USA stockpiling of remdesivir: How should the world respond?. Journal of Comparative Effectiveness Research, 2020, 9, 1243-1246.	1.4	1
23	Translation, cultural adaptation and psychometric validation of the SF-6D measure of health-related quality of life for use in Arabic-Speaking countries. Research in Social and Administrative Pharmacy, 2020, 16, 1754-1759.	3.0	2
24	Cannabidiol with clobazam for seizures associated with Dravet and Lennox-Gastaut syndromes. Lancet Neurology, The, 2020, 19, 290-291.	10.2	1
25	New onset of axial spondyloarthropathy in patients treated with isotretinoin for acne vulgaris: incidence, follow-up, and MRI findings. Clinical Rheumatology, 2020, 39, 1829-1838.	2.2	9
26	Examining the Feasibility and Acceptability of Valuing the Arabic Version of SF-6D in a Lebanese Population. International Journal of Environmental Research and Public Health, 2020, 17, 1037.	2.6	12
27	PNS130 The Appropriateness of EQ-5D across Conditions: A Review of the Literature and NICE Technology Appraisals. Value in Health, 2020, 23, S662.	0.3	1
28	Venous thromboembolism prophylaxis strategies for people undergoing elective total knee replacement: a systematic review and network meta-analysis. Lancet Haematology,the, 2019, 6, e530-e539.	4.6	23
29	Cost Effectiveness of Advanced Pharmacy Services Provided in the Community and Primary Care Settings: A Systematic Review. Pharmacoeconomics, 2019, 37, 1241-1260.	3.3	23
30	NICE NG89 recommendations for extended pharmacological thromboprophylaxis $\hat{a} \in \text{``is it justified}$ and is it cost effective: a rebuttal from the British Society for Haematology $\hat{a} \in ``response to Lester < i>et al British Journal of Haematology, 2019, 186, 788-789.$	2.5	3
31	Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip Replacement: A Systematic Review and Network Meta-Analysis. Value in Health, 2019, 22, 953-969.	0.3	6
32	Pharmaceutical Policy Reforms to Regulate Drug Prices in the Asia Pacific Region: The Case of Australia, China, India, Malaysia, New Zealand, and South Korea. Value in Health Regional Issues, 2019, 18, 18-23.	1.2	20
33	Effectiveness and cost effectiveness of pharmacist input at the ward level: a systematic review and meta-analysis. Research in Social and Administrative Pharmacy, 2019, 15, 1212-1222.	3.0	32
34	Moving the needle—what does RSAP look for and what does it aim to do?. Research in Social and Administrative Pharmacy, 2019, 15, 1-2.	3.0	11
35	Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness, Costs and Health Utilities. Pharmacoeconomics, 2018, 36, 523-532.	3.3	2
36	Basal Insulin Regimens for Adults with Type 1 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis. Value in Health, 2018, 21, 176-184.	0.3	11

#	Article	IF	CITATIONS
37	PMS23 - OPTIMIZING TREATMENT FOR RHEUMATOID ARTHRITIS IN THE KINGDOM OF SAUDI ARABIA (OPTRA). Value in Health, 2018, 21, S291.	0.3	1
38	PCV9 - VENOUS THROMBOEMBOLISM PROPHYLAXIS STRATEGIES FOR PEOPLE UNDERGOING ELECTIVE TOTAL KNEE REPLACEMENT: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS TO INFORM NICE CLINICAL GUIDELINE RECOMMENDATION. Value in Health, 2018, 21, S94.	0.3	0
39	PCV41 - COST IMPACT ANALYSIS OF USING IMPROVE® TOOL FOR VENOUS THROMBOEMBOLISM RISK ASSESSMENT IN MEDICAL PATIENTS ADMITTED TO THE UK NHS HOSPITALS TO INFORM NICE CLINICAL GUIDELINE RECOMMENDATION. Value in Health, 2018, 21, S99.	0.3	0
40	Cost-Utility Analysis of Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip and Total Knee Replacement Surgeries in the English National Health Service. Frontiers in Pharmacology, 2018, 9, 1370.	3.5	19
41	Myelodysplasia in a psoriasis patient receiving etanercept: Cause or coincidence?. Indian Journal of Dermatology, Venereology and Leprology, 2018, 84, 463.	0.6	1
42	Basal Insulin Regimens for Adults with Type 1 Diabetes Mellitus: A Cost-Utility Analysis. Value in Health, 2017, 20, 1279-1287.	0.3	5
43	Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness and Cost-Effectiveness Analyses. Value in Health, 2017, 20, A408.	0.3	0
44	Economic Evaluation and Its Types. , 2017, , 99-119.		1
45	Intravenous Fluids for Children: Cost and Threshold Analysis to Inform the National Institute for Health and Care Excellence (NICE) Clinical Guideline Recommendation. Value in Health, 2016, 19, A607.	0.3	0
46	A Systematic Review of Patients' Perspectives on the Subcutaneous Route of Medication Administration. Patient, 2016, 9, 281-292.	2.7	22
47	Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches. Pharmacoeconomics, 2016, 34, 447-461.	3.3	30
48	Evaluation of a protocolâ€based intervention to promote timely switching from intravenous to oral paracetamol for postâ€operative pain management: an interrupted time series analysis. Journal of Evaluation in Clinical Practice, 2015, 21, 1081-1088.	1.8	7
49	Intravenous fluids in children and young people: summary of NICE guidance. BMJ, The, 2015, 351, h6388.	6.0	16
50	Evaluation of a consultant audit and feedback programme to improve the quality of antimicrobial prescribing in acute medical admissions. International Journal of Pharmacy Practice, 2015, 23, 333-339.	0.6	9
51	Diagnosis and management of type 1 diabetes in adults: summary of updated NICE guidance. BMJ, The, 2015, 351, h4188.	6.0	27
52	Basal Insulin Regimens: Systematic Review, Network Meta-Analysis, and Cost - Utility Analysis for the National Institute For Health and Care Excellence (Nice) Clinical Guideline on Type 1 Diabetes Mellitus in Adults. Value in Health, 2015, 18, A339.	0.3	1
53	Antibiotic dispensing in Egyptian community pharmacies: An observational study. Research in Social and Administrative Pharmacy, 2014, 10, 168-184.	3.0	84
54	A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials, 2014, 15, 14.	1.6	89

#	Article	IF	CITATIONS
55	A Systematic Review of Patient Preferences for Subcutaneous Medications. Value in Health, 2013, 16, A335-A336.	0.3	0
56	Translation and Cultural Adaptation of the SF-6D Questionnaire for Use in Arabic-Speaking Countries. Value in Health, 2013, 16, A606.	0.3	2
57	Factors affecting the motivation of healthcare professionals providing care to Emiratis with type 2 diabetes. JRSM Short Reports, 2013, 4, 1-13.	0.6	16
58	OP22â€Projections of Healthcare Costs in the Last Year of life for Older Cancer Patients in European Union Member States (2008-2030). Journal of Epidemiology and Community Health, 2012, 66, A9.1-A9.	3.7	0
59	Unlicensed use of metformin in children and adolescents in the UK. British Journal of Clinical Pharmacology, 2012, 73, 135-139.	2.4	38
60	Pharmacist supplementary prescribing: A step toward more independence?. Research in Social and Administrative Pharmacy, 2011, 7, 246-256.	3.0	30
61	Hospital admissions for asthma, diabetes and COPD: is there an association with practice nurse staffing? A cross sectional study using routinely collected data. BMC Health Services Research, 2010, 10, 276.	2.2	20
62	Effects of interruptions to nurses during medication administration. Nursing Management, 2010, 16, 22-23.	0.2	13
63	KNOWLEDGE AND PERCEPTIONS OF VITAMIN D DEFICIENCY AMONG THE UNITED ARAB EMIRATES POPULATION. Asian Journal of Pharmaceutical and Clinical Research, 0, , 183-186.	0.3	5